Table 2.
Participants, interventions, outcomes and results
| Studyref. no. | Participants | Interventions | Outcomes measures of interest for the review |
|---|---|---|---|
| Al-Nowaiser et al. (2014)23 | Test group: N baseline = 38 N end of trial = 35 |
Test group: 6–8 sessions of SRP. After 45 days, re-evaluation and subgingival debridement + antimicrobial dose of systemic DOXY 100 mg once a day for 14 days with a loading dose of 200 mg on the first day | Test Overall CAL gain: 0.74 ± 0.17 mm Overall probing depth reduction: 1.5 ± 0.38 mm |
| Control group: N baseline = 38 N end of trial = 33 |
Control group: 6–8 sessions of SRP. After 45 days, re-evaluation and subgingival debridement | Control Overall CAL gain: 0.96 ± 0.22 mm Overall probing depth reduction: 1.4 ± 0.28 mm |
|
| Al-Zahrani et al. (2009)24 | Test group: N baseline = 15 N end of trial = 14 |
Test group: 1–4 sessions of SRP + DOXY 200 mg on the first day and DOXY 100 mg once daily for 13 days |
Test Overall CAL gain: 0.49 ± 0.64 mm Overall probing depth reduction: 0.44 ± 0.38 mm Reduction of sites with probing depth ≥5: 0.1 |
| Control group: N baseline = 15 N end of trial = 15 Note: PDT group = 15 |
Control group: 1–4 sessions of SRP only |
Control Overall CAL gain: 0.56 ± 1.14 mm Overall probing depth reduction: 0.6 ± 0.67 mm Reduction of sites with probing depth ≥5: 0.06 |
|
| Botero et al. (2013)25/Hincapié et al. (2014)34 | Test group: N baseline = 33 N end of trial = 28 |
Test group: subgingival scaling in a single session + systemic AZT 500 mg/day for 3 days | Test Overall CAL gain: 0.2 ± 0.75 mm Overall probing depth reduction: 0.6 ± 0.51 mm |
| Control group: N baseline = 37 N end of trial = 31 |
Control group: subgingival scaling in a single session + placebo | Control Overall CAL gain: 0.3 ± 1.08 mm Overall probing depth reduction: 0.4 ± 0.62 mm |
|
| Gaikwad et al. (2013)26 | Test group: N baseline = 25 N end of trial = not reported |
Test group: full-mouth SRP + systemic DOXY 100 mg once a day for 15 days | Test Overall CAL gain: 0.93 ± 0.45 mm Overall probing depth reduction: 0.69 ± 0.11 mm |
| Control group: N baseline = 25 N end of trial = not reported |
Control group: full-mouth SRP only | Control Overall CAL gain: 0.47 ± 0.52 mm Overall probing depth reduction: 0.52 ± 0.34 mm |
|
| Grossi et al. (1997)27 | Test group: N baseline = not reported N end of trial = not reported |
Test group: SRP + water irrigation + systemic DOXY 100 mg | Test Overall CAL gain: 0.54 ± 0.3 mm Overall probing depth reduction: 0.72 ± 0.2 mm |
| Control group: N baseline = not reported N end of trial = not reported |
Control group: SRP + water irrigation + placebo SRP in two sessions (half of the mouth in each session) and irrigation with water. Doxycycline 100 mg or placebo per day for 2 weeks starting in the first session of SRP |
Control Overall CAL gain: 0.4 ± 0.2 mm Overall probing depth reduction: 0.56 ± 0.1 mm |
|
| Llambés et al. (200513 #bib200838 #bib201239) | Test group: N baseline = 30 N end of trial = 30 |
Test group: SRP in one or two sessions plus chlorhexidine 0.2% rinses (20 ml for 30 s, twice daily) for 12 weeks plus systemic DOXY 100 mg (twice daily for the first day and then one capsule/day thereafter) for 15 days | Test Overall CAL gain: 0.45 ± 0.55 mm Overall probing depth reduction: 0.74 ± 0.46 mm |
| Control group: N baseline = 30 N end of trial = 30 |
Control group: SRP in one or two sessions plus chlorhexidine 0.2% rinses (20 ml for 30 s, twice daily) | Control Overall CAL gain: 0.42 ± 0.37 mm Overall probing depth reduction: 0.65 ± 0.33 mm |
|
| O’Connel et al. (2008)28 | Test group: N baseline: not reported N end of trial: 15 |
Test group: full-mouth SRP + systemic DOXY 100 mg | Test Overall CAL gain: 0.9 ± 1.6 mm Overall probing depth reduction: 1.1 ± 0.4 mm Reduction of sites with probing depth 4–5 mm: 21.8 Reduction of sites with probing depth ≥6 mm: 5.0 |
| Control group: N baseline: not reported N end of trial: 15 |
Control group: full-mouth SRP + placebo 2–4 sessions of SRP within 24 to 36 hours plus systemic DOXY 100 mg or placebo for 14 days after an initial dose of 200 mg (the antibiotic or placebo therapy started the day before SRP was performed) |
Control Overall CAL gain: 0.5 ± 1.35 mm Overall probing depth reduction: 0.8 ± 0.7 mm Reduction of sites with probing depth 4–5 mm: 18.7 Reduction of sites with probing depth ≥6 mm: 8.9 |
|
| Rodrigues et al. (2003)29 | Test group: N baseline: 15 N end of trial: not reported |
Test group: full-mouth SRP in two sessions within 24–6 hours. One day before the first session, AMOX/clavulanic acid 875 mg was systemically administered twice daily for 2 weeks |
Test Overall CAL gain: 0.0 ± 1.2 mm Overall probing depth reduction: 0.8 ± 0.6 mm |
| Control group: N baseline: 15 N end of trial: not reported |
Control group: full-mouth SRP in two sessions within 24–36 hours only | Control Overall CAL gain: 0.0 ± 1.35 mm Overall probing depth reduction: 0.9 ± 0.7 mm |
|
| Singh et al. (2008)30 | Test group: N baseline: 15 N end of trial: not mentioned |
Test group: full-mouth SRP plus systemic DOXY 100 mg daily for 14 days (200 mg in the first day) | Test Overall CAL gain: 0.34 ± 0.61 mm Overall probing depth reduction: 0.38 ± 0.47 mm |
| Control group: N baseline: 15 N end of trial: not mentioned |
Control group: full-mouth SRP only | Control Overall CAL gain: 0.3 ± 0.45 mm Overall probing depth reduction: 0.34 ± 0.35 mm |
|
| Miranda et al. (2014)41/Tamashiro et al. (2016)15 | Test group: N baseline: 29 N end of trial: 16 |
Test group: SRP + systemic MTZ 400 mg and AMOX 500 mg | Test Overall CAL gain: 0.9 ± 1.08 mm Moderate sites (probing depth 4–6 mm) CAL gain: 1.42 ± 0.10 mm Deep sites (probing depth ≥7 mm) CAL gain: 3.35 ± 0.26 mm Overall probing depth reduction: 1.1 ± 0.43 mm Moderate sites (probing depth 4–6 mm) probing depth reduction: 1.89 ± 0.10 mm Deep sites (probing depth ≥7 mm) probing depth reduction: 4.32 ± 0.24 mm Reduction of sites with probing depth ≥5 mm: 29.14 ± 1.68 Reduction of sites with probing depth ≥6 mm: 14.85 ± 1.12 |
| Control group: N baseline: 29 N end of trial: 17 |
Control group: SRP + placebo After the first session of SRP, the antibiotics (MTZ 400 mg and AMOX 500 mg) or placebo were administered three times daily for 14 days |
Control Overall CAL gain: 0.5 ± 0.85 mm Moderate sites (probing depth 4–6 mm) CAL gain: 0.88 ± 0.10 mm Deep sites (probing depth ≥7 mm) CAL gain: 2.39 ± 0.25 mm Overall probing depth reduction: 0.7 ± 0.6 mm Moderate sites (probing depth 4–6 mm) probing depth reduction: 1.19 ± 0.10 mm Deep sites (probing depth ≥7 mm) probing depth reduction: 2.82 ± 0.24 mm Reduction of sites with probing depth ≥5 mm: 18.69 ± 1.74 Reduction of sites with probing depth ≥6 mm: 10.49 ± 1.16 |
|
| Tsalikis et al. (2014)31 | Test group: N baseline: 35 N end of trial: 31 |
Test group: SRP + systemic DOXY 100 mg |
Test Overall CAL gain: 0.71 ± 0.78 mm Overall probing depth reduction: 0.84 ± 0.74 mm Reduction of sites with probing depth ≥5 mm: 178 |
| Control group: N baseline: 35 N end of trial: 35 |
Control group: SRP + placebo SRP in two sessions plus systemic DOXY 100 mg (200 mg as loading dose and 100 mg for 20 days) or placebo |
Control Overall CAL gain: 0.9 ± 1.1 mm Overall probing depth reduction: 0.76 ± 0.66 mm Reduction of sites with probing depth ≥5 mm: 198 |
AMOX, amoxicillin; AZT, azithromycin; CAL, clinical attachment level; DOXY, doxycycline; HbA1c, glycated haemoglobin; MTZ, metronidazole; PDT, photodynamic therapy; SRP, scaling and root planing.